|
|
|
原研机构- |
|
|
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain
The purpose of this study is to evaluate the effectiveness of Hoat Huyet Nhat Nhat on the reduction of common symptoms related to the insufficient blood supply to the brain such as headache, vertigo, dizziness, sleep disorders and forgetfulness; compared with Gingko Biloba Egb761 (Tanakan) after 45 days of treatment
A Randomized, Active-Control, Open Label, Phase IIIb Study to Evaluate the Safety and Efficacy of TONKA Compared With Silymarin (Legalon) for Lowering Hepatic Enzymes in Liver Function Disorder Patients With Moderate to High Elevated Liver
The purpose of this study is to evaluate the efficacy TONKA on the reduction of ALT and AST in moderate to severe liver enzyme elevated patients; compared with Silymarin (Legalon) after 6 weeks of treatment.
100 项与 Nhat Nhat Pharmaceutical Co.,Ltd 相关的临床结果
0 项与 Nhat Nhat Pharmaceutical Co.,Ltd 相关的专利(医药)
100 项与 Nhat Nhat Pharmaceutical Co.,Ltd 相关的药物交易
100 项与 Nhat Nhat Pharmaceutical Co.,Ltd 相关的转化医学